


## **AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the present Application.

## Listing of Claims

1. (Canceled)
2. (Currently amended) A compound of the formula(II):



II

wherein:

$R_1$  is selected from the group consisting of:

$$-\text{X}'-\text{C}(\text{O})-\text{N}(\text{R}_1')(\text{R}_1'') \text{ and}$$

$$-\text{X}''-\overset{\text{(CH}_2\text{)}_a}{\text{C}(\text{O})-\text{N}}\begin{cases} \text{(CH}_2\text{)}_b \\ \text{A}' \end{cases}$$

$X'$  is selected from the group consisting of  $-\text{CH}(\text{R}_9)-$ ,  $-\text{CH}(\text{R}_9)\text{-alkylene-}$ , and  $-\text{CH}(\text{R}_9)\text{-alkenylene-}$ ;

X" is selected from the group consisting of -CH(R<sub>9</sub>)-, -CH(R<sub>9</sub>)-alkylene-, and -CH(R<sub>9</sub>)-alkenylene-; wherein the alkylene and alkenylene are optionally interrupted with one or more -O-groups;

$R_1'$  and  $R_1''$  are independently selected from the group consisting of:

hydrogen,  
alkyl,  
alkenyl,

aryl,  
arylalkylenyl,  
heteroaryl,  
heteroarylalkylenyl,  
heterocyclyl,  
heterocyclylalkylenyl, and  
alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or  
heterocyclylalkylenyl, substituted by one or more substituents selected from the group  
consisting of:

hydroxy,  
alkyl,  
haloalkyl,  
hydroxyalkyl,  
alkoxy,  
haloalkoxy,  
halogen,  
cyano,  
nitro,  
amino,  
alkylamino,  
dialkylamino,  
arylsulfonyl, and  
alkylsulfonyl;

$A'$  is selected from the group consisting of  $-O-$ ,  $-C(O)-$ ,  $-CH_2-$ ,  $-S(O)_{0-2}-$ , and  $-N(Q-R_4)-$ ;  
a and b are independently integers from 1 to 6 with the proviso that  $a + b$  is  $\leq 7$ ;

~~$R_A$  and  $R_B$  are independently selected from the group consisting of:~~

~~hydrogen,~~  
~~halogen,~~  
~~alkyl,~~

alkenyl,  
alkoxy,  
alkylthio, and  
 $-N(R_9)_2;$

or  $R_A$  and  $R_B$  are taken together to form either a fused aryl ring that is unsubstituted or substituted by one or more  $R_a$  groups, or a fused 5 to 7 6-membered saturated ring that is unsubstituted or substituted by one or more  $R_c$  groups;

~~or  $R_A$  and  $R_B$  taken together form a fused heteroaryl or 5 to 7 membered saturated ring containing one heteroatom selected from the group consisting of N and S, wherein the heteroaryl ring is unsubstituted or substituted by one or more  $R_b$  groups, and the 5 to 7 membered saturated ring is unsubstituted or substituted by one or more  $R_e$  groups;~~

$R_a$  is selected from the group consisting of :

halogen,  
alkyl,  
haloalkyl,  
alkoxy, and  
 $-N(R_9)_2;$

~~$R_b$  is selected from the group consisting of:~~

~~halogen,  
hydroxy,  
alkyl,  
haloalkyl,  
alkoxy, and  
 $-N(R_9)_2;$~~

$R_c$  is selected from the group consisting of:

halogen,  
hydroxy,  
alkyl,  
alkenyl,

haloalkyl,  
alkoxy,  
alkylthio, and  
-N(R<sub>9</sub>)<sub>2</sub> ;


R<sub>2</sub> is selected from the group consisting of:

hydrogen, alkyl, alkoxyalkyl, and hydroxyalkyl;  
-R<sub>4</sub>;  
-X R<sub>4</sub>;  
-X Y R<sub>4</sub>, and  
-X R<sub>5</sub>;

X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups are optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more O groups;


Y is selected from the group consisting of:

-S(O)<sub>0-2</sub>-,  
-S(O)<sub>2</sub>-N(R<sub>8</sub>)-,  
-C(R<sub>6</sub>)-,  
-C(R<sub>6</sub>)-O-,  
-O-C(O)-O-,  
-N(R<sub>8</sub>)-Q-,  
-C(R<sub>6</sub>)-N(R<sub>8</sub>)-,  
-O-C(R<sub>6</sub>)-N(R<sub>8</sub>)-,  
-C(R<sub>6</sub>)-N(OR<sub>9</sub>)-,



$R_4$  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups are unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

$R_5$  is selected from the group consisting of:



$R_6$  is selected from the group consisting of =O and =S;

$R_7$  is  $C_{2-7}$  alkylene;

$R_8$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

$R_9$  is selected from the group consisting of hydrogen and alkyl;

$R_{10}$  is  $C_{3-8}$  alkylene;

$A$  is selected from the group consisting of  $O$ ,  $C(O)$ ,  $S(O)_{0-2}$ ,  $CH_2$ , and  $(R_4)$ ;

$Q$  is selected from the group consisting of a bond,  $-C(R_6)-$ ,  $-C(R_6)-C(R_6)-$ ,  $-S(O)_{2-}$ ,  $-C(R_6)-N(R_8)-W-$ ,  $-S(O)_{2-}N(R_8)-$ ,  $-C(R_6)-O-$ , and  $-C(R_6)-N(OR_9)-$ ; and

$V$  is selected from the group consisting of  $C(R_6)$ ,  $O-C(R_6)$ ,  $N(R_8)-C(R_6)$ , and  $-S(O)_{2-}$ ; and


$W$  is selected from the group consisting of a bond,  $-C(O)-$ , and  $-S(O)_{2-}$ ;

with the proviso that when  $R_A$  and  $R_B$  form a fused heteroaryl or 5 to 7 membered saturated ring containing one heteroatom selected from the group consisting of N and S, wherein the heteroaryl ring is unsubstituted or substituted by one or more  $R_b$  groups, and the 5 to 7 membered saturated ring is unsubstituted or substituted by one or more  $R_e$  groups, then  $R_f$  can also be  $X''-C(O)-N(R_4')(R_4'')$ ;

or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Currently amended) A compound of the formula (IV):




IV

wherein :

$R_{1-1}$  is selected from the group consisting of:

$-X'-C(O)-N(R_1')(R_1'')$  and



$X'$  is selected from the group consisting of  $-CH(R_9)-$ ,  $-CH(R_9)$ -alkylene-, and  $-CH(R_9)$ -alkenylene-;

$X''$  is selected from the group consisting of  $-CH(R_9)-$ ,  $CH(R_9)$ -alkylene-, and  $-CH(R_9)$ -alkenylene-; wherein the alkylene and alkenylene are optionally interrupted with one or more  $-O-$  groups;

$R_1'$  and  $R_1''$  are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxy,

alkyl,

haloalkyl,

hydroxyalkyl,

alkoxy,

haloalkoxy,

halogen,

cyano,  
nitro,  
amino,  
alkylamino,  
dialkylamino,  
arylsulfonyl, and  
alkylsulfonyl ;

A' is selected from the group consisting of -O-, -C(O)-, -CH<sub>2</sub>-, -S(O)<sub>0-2-</sub>, and -N(Q-R<sub>4</sub>)-;

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7;

R<sub>a</sub> is selected from the group consisting of:

halogen,  
alkyl,  
haloalkyl,  
alkoxy, and  
-N(R<sub>9</sub>)<sub>2</sub>

n is an integer from 0 to 4;

R<sub>2</sub> is selected from the group consisting of:



hydrogen, alkyl, alkoxyalkyl, and hydroxylalkyl;  
-R<sub>4</sub>;  
-X R<sub>45</sub>;  
-X Y R<sub>4</sub>, and  
-X R<sub>5</sub>:

~~X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups are optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more O-groups;~~

~~Y is selected from the group consisting of:~~

~~-S(O)<sub>0-2-</sub>,~~  
~~-S(O)<sub>2</sub>-N(R<sub>8</sub>)-,~~


$\text{-C(R}_6\text{)-}$ ,  
 $\text{-C(R}_6\text{)O-}$ ,  
 $\text{-O-C(R}_6\text{)-}$ ,  
 $\text{-O-C(O)-O-}$ ,  
 $\text{-N(R}_8\text{)Q-}$ ,  
 $\text{-C(R}_6\text{)-N(R}_8\text{)-}$ ,  
 $\text{-O-C(R}_6\text{)-N(R}_8\text{)-}$ ,  
 $\text{(R}_6\text{)N(OR}_9\text{)-}$ ,



$R_4$  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups are unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino,

alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

~~R<sub>5</sub> is selected from the group consisting of:~~



~~R<sub>6</sub> is selected from the group consisting of =O and =S;~~

~~R<sub>7</sub> is C<sub>2-7</sub> alkylene;~~

~~R<sub>8</sub> is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl ;~~

~~R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl; and~~

~~R<sub>10</sub> is C<sub>3-8</sub> alkylene;~~


~~A is selected from the group consisting of O, C(O), S(O)<sub>0-2</sub>, CH<sub>2</sub>, and N(R<sub>4</sub>);~~

~~Q is selected from the group consisting of a bond, -C(R<sub>6</sub>)-, -C(R<sub>6</sub>)-C(R<sub>6</sub>)-, -S(O)<sub>2</sub>-, -C(R<sub>6</sub>)-N(R<sub>8</sub>)-W-, -S(O<sub>2</sub>-N(R<sub>8</sub>)-, -C(R<sub>6</sub>)-O-, and -C(R<sub>6</sub>)-N(OR<sub>9</sub>)-;~~

~~V is selected from the group consisting of C(R<sub>6</sub>), O-C(R<sub>6</sub>), N(R<sub>8</sub>)-C(R<sub>6</sub>), and -S(O)<sub>2</sub>; and~~

~~W is selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>-; or a pharmaceutically acceptable salt thereof.~~

5. (Currently amended) The compound or salt of claim 2 wherein the compound is of the following formula (V):




V

wherein:

$R_{1-1}$  is selected from the group consisting of:

$-X' -C(O)-N(R_1')(R_1'')$  and



$X'$  is selected from the group consisting of  $-CH(R_9)$ -,  $-CH(R_9)$ -alkylene-, and  $-CH(R_9)$ -alkenylene-;

$X''$  is selected from the group consisting of  $-CH(R_9)$ -,  $-CH(R_9)$ -alkylene-, and  $-CH(R_9)$ -alkenylene-; wherein the alkylene and alkenylene are optionally interrupted with one or more  $-O-$  groups;

$R_1'$  and  $R_1''$  are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxy,

alkyl,

haloalkyl,

hydroxyalkyl,

alkoxy,

haloalkoxy,

halogen,  
cyano,  
nitro,  
amino,  
alkylamino,  
dialkylamino,  
arylsulfonyl, and  
alkylsulfonyl;

A' is selected from the group consisting of -O-, -C(O)-, -CH<sub>2</sub>-, -S(O)<sub>0-2-</sub>, and -N(Q-R<sub>4</sub>)-;  
a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7;

R<sub>c</sub> is selected from the group consisting of:

halogen,  
hydroxy,  
alkyl,  
alkenyl,  
haloalkyl,  
alkoxy,  
alkylthio, and  
-N(R<sub>9</sub>)<sub>2</sub>;

n is an integer from 0 to 4;

R<sub>2</sub> is selected from the group consisting of:


hydrogen, alkyl, alkoxyalkyl, and hydroxyalkyl;  
~~-R<sub>45</sub>,~~  
~~-X R<sub>45</sub>,~~  
~~-X Y R<sub>45</sub>, and~~  
~~-X R<sub>55</sub>;~~

~~X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups are~~

~~optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more —O— groups;~~

~~Y is selected from the group consisting of:~~


- ~~—S(O)<sub>0-2</sub>—,~~
- ~~—S(O)<sub>2</sub>—N(R<sub>8</sub>)—,~~
- ~~—(R<sub>6</sub>)—C(R<sub>6</sub>)—O—,~~
- ~~—O—C(R<sub>6</sub>)—,~~
- ~~—O—C(O)—O—,~~
- ~~—N(R<sub>8</sub>)—Q—,~~
- ~~—C(R<sub>6</sub>)—N(R<sub>8</sub>)—,~~
- ~~—O—C(R<sub>6</sub>)—N(R<sub>8</sub>)—,~~
- ~~—C(R<sub>6</sub>)—N(OR<sub>9</sub>)—,~~



R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups are unsubstituted or

substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

$R_5$  is selected from the group consisting of:



$R_6$  is selected from the group consisting of =O and =S;

$R_7$  is  $C_{2-7}$ -alkylene;

$R_8$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

$R_9$  is selected from the group consisting of hydrogen and alkyl; and

$R_{10}$  is  $C_{3-8}$ -alkylene;

$A$  is selected from the group consisting of O, C(O), S(O)<sub>0-2</sub>, CH<sub>2</sub>, and N(R<sub>4</sub>);

Q is selected from the group consisting of a bond, -C(R<sub>6</sub>)-, -C(R<sub>6</sub>)-C(R<sub>6</sub>)-, -S(O)<sub>2</sub>-, -C(R<sub>6</sub>)-N(R<sub>8</sub>)-W-, -S(O)<sub>2</sub>-N(R<sub>8</sub>)-, -C(R<sub>6</sub>)-O-, and -C(R<sub>6</sub>)-N(OR<sub>9</sub>)-;

$V$  is selected from the group consisting of C(R<sub>6</sub>), O-C(R<sub>6</sub>), N(R<sub>8</sub>)-C(R<sub>6</sub>), and S(O)<sub>2</sub>;  
and

W is selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>;  
or a pharmaceutically acceptable salt thereof.

#### 6.-11. (Canceled)

12. (Previously presented) The compound or salt of claim 4 wherein n is 0.

#### 13. (Canceled)

14. (Previously presented) The compound or salt of claim 2 wherein X' is  $-\text{CH}_2\text{-C}_{0-10}$  alkylene- or X" is  $-\text{CH}_2\text{-C}_{0-10}$  alkylene- or  $-\text{CH}_2\text{-C}_{1-4}$  alkylene-O-C<sub>1-4</sub> alkylene-.

15. (Canceled)

16. (Previously presented) The compound or salt of claim 14 wherein X' is  $-(\text{CH}_2)_{1-5}-$ ,  $-\text{CH}_2\text{C}(\text{CH}_3)_2-$ , or  $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2-$ ; or X" is  $-(\text{CH}_2)_{1-5}-$ ,  $-\text{CH}_2\text{C}(\text{CH}_3)_2-$ ,  $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2-$ , or  $-(\text{CH}_2)_3\text{-O-CH}_2-$ .

17.-25. (Canceled)

26. (Previously presented) The compound or salt of claim 2 wherein R<sub>1</sub> is hydrogen.

27. (Previously presented) The compound or salt of claim 26 wherein R<sub>1</sub>' is hydrogen or C<sub>1-3</sub> alkyl.

28. (Previously presented) The compound or salt of claim 27 wherein R<sub>1</sub>' and R<sub>1</sub>" are hydrogen.

29.-30. (Canceled)

31. (Previously presented) The compound or salt of claim 2 wherein R<sub>2</sub> is hydrogen, C<sub>1-4</sub> alkyl, hydroxy C<sub>1-4</sub> alkylenyl, or C<sub>1-4</sub> alkyl-O-C<sub>1-4</sub> alkylenyl.

32. (Canceled)

33. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 and a pharmaceutically acceptable carrier.


34. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

35. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

36. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

37.-44. (Canceled)

45. (Previously presented) The compound or salt of claim 4 wherein R<sub>1-1</sub> is



46. (Previously presented) The compound or salt of claim 4 wherein X is -CH<sub>2</sub>-C<sub>0-10</sub> alkylene- or X" is -CH<sub>2</sub>-C<sub>0-10</sub> alkylene- or -CH<sub>2</sub>-C<sub>1-4</sub>alkylene-O-C<sub>1-4</sub> alkylene-.

47. (Previously presented) The compound or salt of claim 46 wherein X is -(CH<sub>2</sub>)<sub>1-5</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, or -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-; or X" is -(CH<sub>2</sub>)<sub>1-5</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-, or -(CH<sub>2</sub>)<sub>3</sub>-CH<sub>2</sub>-.

48. (Previously presented) The compound or salt of claim 4 wherein R<sub>1</sub> is hydrogen.


49. (Previously presented) The compound or salt of claim 48 wherein R<sub>1</sub> is hydrogen or C<sub>1-3</sub> alkyl.

50. (Previously presented) The compound or salt of claim 49 wherein R<sub>1</sub>' and R<sub>1</sub>'' are hydrogen.

51. (Previously presented) The compound or salt of claim 4 wherein R<sub>2</sub> is hydrogen, C<sub>1-4</sub> alkyl, hydroxy C<sub>1-4</sub> alkylene, or C<sub>1-4</sub> alkyl-O-C<sub>1-4</sub> alkylene.

52. (Previously presented) The compound or salt of claim 5 wherein n is 0.

53. (Previously presented) The compound or salt of claim 5 wherein R<sub>1-1</sub> is



54. (Previously presented) The compound or salt of claim 5 wherein X is -CH<sub>2</sub>-C<sub>0-10</sub> alkylene- or X'' is -CH<sub>2</sub>-C<sub>0-10</sub> alkylene- or -CH<sub>2</sub>-C<sub>1-4</sub> alkylene-O-C<sub>1-4</sub> alkylene-.

55. (Previously presented) The compound or salt of claim 5 wherein R<sub>1</sub>'' is hydrogen.

56. (Previously presented) The compound or salt of claim 55 wherein R<sub>1</sub>' is hydrogen or C<sub>1-3</sub> alkyl.

57. (Previously presented) The compound or salt of claim 56 wherein R<sub>1</sub>' and R<sub>1</sub>'' are hydrogen.

58. (Previously presented) The compound or salt of claim 5 wherein R<sub>2</sub> is hydrogen, C<sub>1-4</sub> alkyl, hydroxy C<sub>1-4</sub> alkylene, or C<sub>1-4</sub> alkyl-O-C<sub>1-4</sub> alkylene.

59.-63. (Canceled)

64. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 4 and a pharmaceutically acceptable carrier.

65. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 5 and a pharmaceutically acceptable carrier.

66.-67.(Canceled)

68. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 4 to the animal.

69. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 5 to the animal.

70. (Canceled)